Home > Insider Trading > Filing (0001104659-20-004321)

Filing Details

Accession Number:: 0001104659-20-004321
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-01-15 16:11:14
Reporting Period:: 2020-01-13

Accepted Time:: 2020-01-15 16:11:14
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1739426	Osmotica Pharmaceuticals Plc	OSMT	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1705722	Avista Capital Partners Iii Gp, L.p.	C/O Avista Capital Partners Iii 65 East 55Th Street, 18Th Floor New York NY 10022	No	No	Yes	No
1751055	Orbit Co-Invest I Llc	C/O Avista Capital Partners Iii 65 East 55Th Street, 18Th Floor New York NY 10022	No	No	Yes	No
1751056	Orbit Co-Invest Iii Llc	C/O Avista Capital Partners Iii 65 East 55Th Street, 18Th Floor New York NY 10022	No	No	Yes	No
1794239	Avista Healthcare Partners, L.p.	C/O Avista Capital Partners Iii 65 East 55Th Street, 18Th Floor New York NY 10022	No	No	Yes	No
1799895	Avista Healthcare Partners Gp, Ltd.	C/O Avista Capital Partners Iii 65 East 55Th Street, 18Th Floor New York NY 10022	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Acquisiton	2020-01-13	1,250,000	$5.00	15,730,864	No	4	P	Indirect	By Avista Capital investment fund

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Avista Capital investment fund

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Ordinary Shares	4,936,926	Indirect	By Avista Capital investment fund
Ordinary Shares	1,032,995	Indirect	By Avista Capital investment fund

Footnotes

Represents 1,250,000 Ordinary Shares acquired by Avista Healthcare Partners, L.P. ("AHP") in the Issuer's underwritten public offering (the "Offering") that was completed on January 13, 2020. The acquisition price of $5.00 per Ordinary Share represents the public offering price in the Offering paid by AHP and does not give effect to the fee paid by the Issuer to Avista Capital Holdings, L.P., an affiliate of AHP, pursuant to the Fee Letter Agreement, dated January 8, 2020, among the Issuer, Avista Capital Holdings, L.P. and the other parties thereto, which was entered into in connection with the Offering.
Represents shares of the Issuer held by AHP. Avista Healthcare Partners GP, Ltd. ("AHP GP") is the general partner of AHP. As a result, AHP GP may be deemed to share voting and investment power with respect to the shares held by AHP. Each of AHP and AHP GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
Represents shares of the Issuer held by Orbit Co-Invest I LLC. Avista Capital Partners III GP, L.P. ("ACP GP") is the manager of Orbit Co-Invest I LLC. As a result, ACP GP may be deemed to share voting and investment power with respect to the shares held by Orbit Co-Invest I LLC. Each of Orbit Co-Invest I LLC and ACP GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
Represents shares of the Issuer held by Orbit Co-Invest III LLC. ACP GP is the manager of Orbit Co-Invest III LLC. As a result, ACP GP may be deemed to share voting and investment power with respect to the shares held by Orbit Co-Invest III LLC. Each of Orbit Co-Invest III LLC and ACP GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.